Neurocrine Biosciences (NBIX) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.

Does the MarketBeat Community favor ALNY or NBIX?

Alnylam Pharmaceuticals received 129 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.59% of users gave Neurocrine Biosciences an outperform vote while only 76.33% of users gave Alnylam Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1164 76.33%	Underperform Votes 361 23.67%
Neurocrine Biosciences	Outperform Votes 1035 77.59%	Underperform Votes 299 22.41%

Does the media favor ALNY or NBIX?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 33 mentions for Alnylam Pharmaceuticals and 28 mentions for Neurocrine Biosciences. Alnylam Pharmaceuticals' average media sentiment score of 1.19 beat Neurocrine Biosciences' score of 0.66 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	22 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	11 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, ALNY or NBIX?

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500.

Do insiders & institutionals believe in ALNY or NBIX?

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.2% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has higher earnings & valuation, ALNY or NBIX?

Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.25B	14.00	-$278.16M	-$2.17	-111.51
Neurocrine Biosciences	$2.36B	4.34	$341.30M	$3.29	31.39

Do analysts prefer ALNY or NBIX?

Alnylam Pharmaceuticals presently has a consensus price target of $315.58, suggesting a potential upside of 30.42%. Neurocrine Biosciences has a consensus price target of $160.67, suggesting a potential upside of 55.57%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.91

Is ALNY or NBIX more profitable?

Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%
Neurocrine Biosciences	14.49%	13.38%	9.73%

Summary

Neurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 19 factors compared between the two stocks.